Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press75310.17650/2949-5857-2024-14-4-20-30DESCRIPTION OF THE METHODOLOGYОПИСАНИЕ МЕТОДОЛОГИИLimitations of CDX and PDX methods using for cultivation of malignant ovarian neoplasms and their mathematical justificationОб ограничениях применения методов CDX- и PDX-культивирования злокачественных новообразований яичника и их математическое обоснованиеhttps://orcid.org/0000-0003-3210-4704BiktimirovT. R.БиктимировТ. Р.
Russian Federation

40 Mira St., Khanty-Mansiysk, Khanty-Mansiysk Autonomous Region 628011

Ханты-Мансийский автономный округ, 628011 Ханты-Мансийск, ул. Мира, 40

https://orcid.org/0000-0003-1396-5381ShidinV. A.ШидинВ. А.
Russian Federation

Vladimir A. Shidin 

40 Mira St., Khanty-Mansiysk, Khanty-Mansiysk Autonomous Region 628011,

54 Odesskaya St., Tyumen 625023

Владимир Александрович Шидин 

Ханты-Мансийский автономный округ, 628011 Ханты-Мансийск, ул. Мира, 40,

625023 Тюмень, ул. Одесская, 54

vshidin@mail.ruhttps://orcid.org/0000-0001-5723-1246YaninV. L.ЯнинВ. Л.
Russian Federation

40 Mira St., Khanty-Mansiysk, Khanty-Mansiysk Autonomous Region 628011

Ханты-Мансийский автономный округ, 628011 Ханты-Мансийск, ул. Мира, 40

https://orcid.org/0009-0002-1102-0915KuzmenkoM. Ya.КузьменкоМ. Я.
Russian Federation

54 Odesskaya St., Tyumen 625023

625023 Тюмень, ул. Одесская, 54

https://orcid.org/0009-0002-6419-8098KarpovaYa. A.КарповаЯ. А.
Russian Federation

40 Mira St., Khanty-Mansiysk, Khanty-Mansiysk Autonomous Region 628011

Ханты-Мансийский автономный округ, 628011 Ханты-Мансийск, ул. Мира, 40

https://orcid.org/0000-0003-1266-5774KhalikovaL. V.ХаликоваЛ. В.
Russian Federation

54 Odesskaya St., Tyumen 625023

625023 Тюмень, ул. Одесская, 54

Khanty-Mansiysk State Medical Academy, Khanty-Mansiysk Autonomous Region – YugraБУ ВО ХМАО – Югры «Ханты-Мансийская государственная медицинская академия»Tyumen State Medical University of the Ministry of Health of RussiaФГБОУ ВО «Тюменский государственный медицинский университет» Минздрава России3011202414420302911202429112024Copyright ©; 2024, Biktimirov T.R., Shidin V.A., Yanin V.L., Kuzmenko M.Y., Karpova Y.A., Khalikova L.V.Copyright ©; 2024, Биктимиров Т.Р., Шидин В.А., Янин В.Л., Кузьменко М.Я., Карпова Я.А., Халикова Л.В.2024Biktimirov T.R., Shidin V.A., Yanin V.L., Kuzmenko M.Y., Karpova Y.A., Khalikova L.V.Биктимиров Т.Р., Шидин В.А., Янин В.Л., Кузьменко М.Я., Карпова Я.А., Халикова Л.В.https://creativecommons.org/licenses/by/4.0https://onco-surgery.info/jour/article/view/753

The article presents information on the most popular methods of culturing human malignant neoplasms to implement the obtained fundamental knowledge into the basis of translational research in oncology. A brief description of each of them allows you to decide on the possibility of including the technique in experimental work. The first approximation to the formation of the logic of the mathematical justification of the design of an experiment on modeling human malignant neoplasms is given.

Also, using the example of a brief description of the original design of the experiment of scientists from the Khanty-Mansiysk State Medical Academy and the Tyumen State Medical University, the logic of constructing the design of such an experiment as part of the research work is demonstrated. An idea is formed about the need to include fundamental and translational stages in clinical experimental work as part of a unified strategy for responding to the great challenges of personalized medicine. An idea is formed about the need to include fundamental and translational stages in clinical experimental work as part of a unified strategy for responding to the great challenges of personalized medicine.

В статье представлены сведения о наиболее популярных методах культивирования злокачественных новообразований человека для внедрения полученных фундаментальных знаний в основу трансляционных исследований в онкологии. Краткая характеристика каждого из них позволяет принять решение о возможности включения методики в экспериментальные работы. Дано первое приближение к формированию логики математического обоснования дизайна эксперимента по моделированию злокачественных новообразований человека.

Также на примере краткого описания оригинального дизайна эксперимента ученых Ханты-Мансийской государственной медицинской академии и Тюменского государственного медицинского университета продемонстрирована логика построения дизайна подобного эксперимента в рамках исследовательской работы. Сформировано представление о необходимости включения в клинические экспериментальные работы фундаментальных и трансляционных этапов в составе единой стратегии ответа на большие вызовы персонифицированной медицины. Сформировано представление о необходимости включения в клинические экспериментальные работы фундаментальных и трансляционных этапов в составе единой стратегии ответа на большие вызовы персонифицированной медицины.

ovarian cancerin vivo cultivationPDX modelmathematical modelрак яичникакультивирование in vivoмодель PDXматематическая модельOn the Strategy of scientific and technological development of the Russian Federation: Decree of the President of the Russian Federation dated February 28, 2024 No. 145. Collection of legislation of the Russian Federation 2024;10:4653–66.О Стратегии научно-технологического развития Российской Федерации: указ Президента Российской Федерации от 28 февраля 2024 г. № 145. Собрание законодательства РФ 2024;10:4653–66.Porter J.M., McFarlane I., Bartos C. et al. The survival benefit associated with complete macroscopic resection in epithelial ovarian cancer is histotype specific. JNCI Cancer Spectr 2024;8(4):pkae049. DOI: 10.1093/jncics/pkae049Manning-Geist B.L., Chi D.S., Long Roche K. et al. Tertiary cytoreduction for recurrent ovarian carcinoma: an updated and expanded analysis. Gynecol Oncol 2021;162(2):345–52. DOI: 10.1016/j.ygyno.2021.05.015Kim S.R., Parbhakar A., Li X. et al. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with BRCA mutated advanced high grade serous ovarian cancer: 10 year survival analysis. Int J Gynecol Cancer 2024;34(6):879–85. DOI: 10.1136/ijgc-2023-005065De Jong D., Otify M., Chen I. et al. Survival and chemosensitivity in advanced high grade serous epithelial ovarian cancer patients with and without a BRCA germline mutation: more evidence for shifting the paradigm towards complete surgical cytoreduction. Medicina (Kaunas) 2022;58(11):1611. DOI: 10.3390/medicina58111611The state of oncological care for Russian population in 2023. Edited by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024.Состояние онкологической помощи населению России в 2023 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024.Vogelstein B., Papadopoulos N., Velculescu V.E. et al. Cancer genome landscapes. Science 2013;339(6127):1546–58. DOI: 10.1126/science.1235122Liu Y., Wu W., Cai C. et al. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther 2023;8(1):160. DOI: 10.1038/s41392-023-01419-2Beckman R.A. Neutral evolution of rare cancer mutations in the computer and the clinic. NPJ Syst Biol Appl 2024;10(1):110. DOI: 10.1038/s41540-024-00436-3Yee C., Dickson K.A., Muntasir M.N. et al. Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine. Front Bioeng Biotechnol 2022;10:836984. DOI: 10.3389/fbioe.2022.836984Cortesi M., Warton K., Ford C.E. Beyond 2D cell cultures: how 3D models are changing the in vitro study of ovarian cancer and how to make the most of them. Peer J 2024;12:e17603. DOI: 10.7717/peerj.17603Adams K.M., Wendt J.R., Wood J. et al. Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancer cell lines and isogenic models. bioRxiv [Preprint]. 2024: 2024.07.26.605381. DOI: 10.1101/2024.07.26.605381Ruibin J., Guoping C., Zhiguo Z. et al. Establishment and characterization of a highly metastatic ovarian cancer cell line. Biomed Res Int 2018;2018:3972534. DOI: 10.1155/2018/3972534Fogh J., Fogh J.M., Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. JNCI: Journal of the National Cancer Institute 1977;59(1):221–6. DOI: 10.1093/jnci/59.1.221Xu S.-H., Qin L.-J., Mou H.-Z. et al. Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. J Exp Clin Cancer Res 1999;18:233–9. PMID: 10464713Li L., Hanahan D. Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. Cell 2013;153(1):86–100. DOI: 10.1016/j.cell.2013.02.051Dsouza V.L., Kuthethur R., Kabekkodu S.P., Chakrabarty S. Organ-on-Chip platforms to study tumor evolution and chemosensitivity. Biochim Biophys Acta Rev Cancer 2022;1877(3):188717. DOI: 10.1016/j.bbcan.2022.188717Carvalho M.R., Barata D., Teixeira L.M. et al. Colorectal tumor-on-a-chip system: a 3D tool for precision onco-nanomedicine. Sci Adv 2019;5(5):eaaw1317. DOI: 10.1126/sciadv.aaw1317Herndler-Brandstetter D., Shan L., Yao Y. et al. Humanized mouse model supports development, function, and tissue residency of human natural killer cells. Proc Natl Acad Sci USA 2017;114(45):E9626–E9634. DOI: 10.1073/pnas.1705301114Zeleniak A., Wiegand C., Liu W. et al. De novo construction of T cell compartment in humanized mice engrafted with iPSC-derived thymus organoids. Nat Methods 2022;19(10):1306–19. DOI: 10.1038/s41592-022-01583-3Topp M.D., Hartley L., Cook M. et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol 2014;8(3):656–68. DOI: 10.1016/j.molonc.2014.01.008Cybulska P., Stewart J.M., Sayad A. et al. A genomically characterized collection of high-grade serous ovarian cancer xenografts for preclinical testing. Am J Pathol 2018;188(5):1120–31. DOI: 10.1016/j.ajpath.2018.01.019George E., Kim H., Krepler C. et al. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2017;2(1):e89760. DOI: 10.1172/jci.insight.89760De Thaye E., Van de Vijver K., Van der Meulen J. et al. Establishment and characterization of a cell line and patientderived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma. Sci Rep 2020;10(1):6688. DOI: 10.1038/s41598-020-63738-6Ricci F., Guffanti F., Affatato R. et al. Establishment of patientderived tumor xenograft models of mucinous ovarian cancer. Am J Cancer Res 2020;10(2):572–80.Ricci F., Bizzaro F., Cesca M. et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res 2014;74(23):6980–90. DOI: 10.1158/0008-5472.CAN-14-0274Colombo P.E., du Manoir S., Orsett B. et al. Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure. Oncotarget 2015;6(29):28327–40. DOI: 10.18632/oncotarget.5069Weroha S.J., Becker M.A., Enderica-Gonzalez S. et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res 2014;20(5):1288–97. DOI: 10.1158/1078-0432.CCR-13-2611Cogno N., Axenie C., Bauer R., Vavourakis V. Agent-based modeling in cancer biomedicine: applications and tools for calibration and validation. Cancer Biol Ther 2024;25(1):2344600. DOI: 10.1080/15384047.2024.2344600Sové R.J., Jafarnejad M., Zhao C. et al. QSP-IO: a quantitative systems pharmacology toolbox for mechanistic multiscale modeling for immuno-oncology applications. CPT Pharmacometrics Syst Pharmacol 2020;9(9):484–97. DOI: 10.1002/psp4.12546Laukien F.H. The evolution of evolutionary processes in organismal and cancer evolution. Prog Biophys Mol Biol 2021;165:43–8. DOI: 10.1016/j.pbiomolbio.2021.08.008